Cost-effectiveness of pemetrexed plus cisplatin: Malignant pleural mesothelioma treatment in UK clinical practice

Value in Health

Volumn 11, Issue 1, 2008, Pages 4-12

  Cordony, Anna ^a   Le Reun, Corinne ^a   Smala, Antje ^a   Symanowski, James T ^b   Watkins, Jessamy ^b  

^a M TAG Pty Ltd   (Australia)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Cisplatin; Cost effectiveness; Malignant pleural mesothelioma; Pemetrexed; United Kingdom

Indexed keywords

CISPLATIN; CYANOCOBALAMIN; DEXAMETHASONE; FOLIC ACID; MITOMYCIN C; NAVELBINE; PEMETREXED; PLATINUM COMPLEX; VINBLASTINE;

ARTICLE; CANCER SURVIVAL; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RASH; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT;

EID: 38549113910     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2007.00209.x     Document Type: Article

References (20)

1. Hodgson JT, McElvenny DM, Darnton AJ, et al. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer 2005 92 : 587 93.
2. Antman KH, Schiff PB, Pass HI. Benign and malignant mesothelioma. In : DeVita VT Jr., Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology (5th ed.). Philadelphia, PA : Lippincott-Raven, 1997.
3. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003 21 : 2636 44.
4. Curtis L, Netten A. Unit Costs of Health and Social Care. Personal Social Services Research Unit (PSSRU). Kent, UK : University of Kent, 2004.
5. British Medical Association and Royal Pharmaceutical Society of Great Britain (2004) British National Formulary (BNF). BNF 2004;49, March 2004.
6. eMIMS, Version 5.0. 2005.
7. Department of Health (2004) NHS Reference Costs 2003 and National Tariff 2004 (Payment by Results Core Tools 2004). Appendix 4. Outpatient; TDC - D98 - Chemotherapy with a Respiratory System Primary Diagnosis. Inpatient; TELIP - D98 - Chemotherapy with a Respiratory System Primary Diagnoses. Available from: http://www.dh.gov.uk/PublicationsAndStatistics/Publications/ PublicationsPolicyAndGuidance/PublicationsPolicyAndGuidanceArticle/fs/en? CONTENT_ID=4070195&chk=UzhHA3 [Accessed June 1, 2005].
8. Department of Health (UK) (2005) Reference Costs 2004. Appendix SRC4. Available from: http://www.dh.gov.uk/PublicationsAndStatistics/Publications/ PublicationsPolicyAndGuidance/fs/en [Accessed July 1, 2005].
9. Medicines.org.UK. Available from: http://www.medicines.org.uk [Accessed January 15, 2007].
10. Bischoff H, Anderson H, Riska S, et al. Palliative chemotherapy of non-small cell lung cancer (NSCLC): baseline data analysis of the ACTION observational study in five European countries. J Clin Oncol ASCO Annu Meeting Proc 2005 3 : 7216.
11. Ahmed N, Ahmedzai S, Vora V, et al. Supportive care for patients with gastro-intestinal cancer. Cochrane Database Syst Rev 2004 3 : CD003445.
12. Andreopolou E, Ross PJ, O'Brien ME, et al. The palliative benefits of MVP chemotherapy in patients with malignant mesothelioma. Ann Oncol 2004 15 : 1406 12.
13. Middleton GW, Smith IE, O'Brien ME, et al. Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma. Ann Oncol 1998 9 : 269 73.
14. Steele JP, Shamash J, Evans MT, et al. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 2000 18 : 3912 17.
15. Fennell DA, Steele JPC, Shamash J, et al. Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma. Lung Cancer 2005 47 : 277 81.
16. Chan K, Tan KL, Lee HS, et al. Malignant mesothelioma: experience at the Singapore General Hospital. Ann Acad Med Singapore 2003 32 : 388 91.
17. Calavrezos A, Koschel G, Husselmann H, et al. Malignant mesothelioma of the pleura. A prospective therapeutic study of 132 patients from 1981 to 1985. Klin Wochenschr 1998 66 : 607 13.
18. Clegg A, Scott DA, Hewitson P, et al. Clinical and cost-effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review. Thorax 2000 57 : 20 8.
19. Boyer MJ. The importance of balancing toxicity and efficacy in chemotherapy, focus on pemetrexed. Am J Cancer 2005 4 : 127 36.
20. Boyer MJ, Jassem J, Liepa AM, et al. Symptom and quality of life advantages for pemetrexed + cisplatin versus cisplatin in treatment of malignant pleural mesothelioma. Lung Cancer 2003 41 (Suppl. 2 S19.